title: Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma.
abstract: OBJECTIVE
  Upper tract transitional cell carcinoma (UTTCC) is a relatively rare tumor. Overall 5-year disease specific survival is in the range of 16.5% to 95% depending on stage. In this study we evaluated predictors associated with disease recurrence and disease specific survival.
  
  
  METHODS
  We report on 129 patients with a median age of 68 years who underwent nephroureterectomy for UTTCC between July 1989 and June 2002. A total of 67 patients had primary UTTCC and 62 had previous (52) or synchronous (10) transitional cell carcinoma of the bladder (BTCC). Medical records were reviewed and analyzed for possible prognostic predictors (primary tumor stage, grade, multifocality, carcinoma in situ, symptoms and signs at presentation, sex, and history of smoking). Disease specific survival and freedom from bladder recurrence were assessed with the Kaplan-Meier method, and differences between the groups were compared using the log rank test. The Cox proportional hazards regression model was used to assess the significance of each predictor.
  
  
  RESULTS
  Disease specific death was reported for 44 patients. In a multivariate analysis using previous BTCC as a predictor (categorized as superficial, invasive or none), primary disease stage and history of BTCC were associated with disease specific survival (p = 0.001 and p = 0.018). History of BTCC grouped the patients into distinct populations in terms of disease specific survival and freedom from bladder recurrence.
  
  
  CONCLUSIONS
  This study demonstrates that a history of BTCC (invasive or superficial) has an adverse effect on the prognosis of patients diagnosed with UTTCC independent of primary tumor stage.
authors.affiliation: Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Mullerad
authors.forename: Paul
authors.initials: P
authors.lastname: Russo
authors.forename: Dragan
authors.initials: D
authors.lastname: Golijanin
authors.forename: Hui Ni
authors.initials: HN
authors.lastname: Chen
authors.forename: Harold H
authors.initials: HH
authors.lastname: Tsai
authors.forename: S Machele
authors.initials: SM
authors.lastname: Donat
authors.forename: Bernard H
authors.initials: BH
authors.lastname: Bochner
authors.forename: Harry W
authors.initials: HW
authors.lastname: Herr
authors.forename: Joel
authors.initials: J
authors.lastname: Sheinfeld
authors.forename: Pramod C
authors.initials: PC
authors.lastname: Sogani
authors.forename: Michael W
authors.initials: MW
authors.lastname: Kattan
authors.forename: Guido
authors.initials: G
authors.lastname: Dalbagni
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002295:Carcinoma, Transitional Cell / Q000401:mortality*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000401:mortality*; D009378:Neoplasms, Multiple Primary / Q000401:mortality*; D011379:Prognosis; D015996:Survival Rate; D014516:Ureteral Neoplasms / Q000401:mortality*; D001749:Urinary Bladder Neoplasms / Q000401:mortality*